Exelixis' High Stakes Gamble on Zanzalintinib Exelixis has been a solid investment over the past five years, with its shares climbing 101%.
However, the biotech company's future hinges on the success of its next gen cancer drug, zanzalintinib.
This investigational medicine is currently awaiting regulatory approval for metastatic colorectal cancer and is being tested in patients with renal cell carcinoma.